Glycoprotein IIb/IIIa inhibitors and no-reflow

Journal of the American College of Cardiology

Volumn 43, Issue 2, 2004, Pages 284-286

  Kloner, Robert A ^a,b,c   Dai, Wangde ^a  

^a Good Samaritan Hospital   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c GOOD SAMARITAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARIPORIDE; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; TIROFIBAN; TYROSINE;

ANIMAL; ANIMAL MODEL; BLOOD CLOT LYSIS; CONTRAST ECHOCARDIOGRAPHY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY LIGATION; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY THROMBOSIS; DRUG EFFECT; DRUG MECHANISM; EDITORIAL; HEART INFARCTION; HEART MUSCLE PERFUSION; HEART MUSCLE REPERFUSION; HUMAN; METHODOLOGY; MICROCIRCULATION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE MYOCARDIAL CONTRAST ECHOCARDIOGRAPHY; REPERFUSION INJURY; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS; VASCULAR PATENCY;

EID: 1042287366     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2003.11.005     Document Type: Editorial

References (21)

1. Kloner R.A., Ganote C.E., Jennings R.B. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 54:1974;1496-1508.
2. Rezkalla S.H., Kloner R.A. No reflow phenomenon. Circulation. 105:2002;656-662.
3. Reffelmann T., Kloner R.A. The "no-reflow" phenomenon basic science and clinical correlates . Heart. 87:2002;162-168.
4. Ito H., Okamura A., Iwakura K., et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation. 93:1996;1993-1999.
5. Kenner M.D., Zajac E.J., Kondos G.T., et al. Ability of the no-reflow phenomenon during an acute myocardial infarction to predict left ventricular dysfunction at one-month follow-up. Am J Cardiol. 76:1995;861-868.
6. Wu K.C., Zerhouni E.A., Judd R.M., et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation. 97:1998;765-772.
7. Kloner R.A., Alker K.J. Effect of streptokinase on intramyocardial hemorrhage, infarct size, and the no-reflow phenomenon during coronary reperfusion. Circulation. 70:1984;513-521.
8. Kloner R.A., Alker K.A., Campbell C., Figures G., Eisenhauer A., Hale S. Does tissue plasminogen activator have direct beneficial effects on the myocardium independent of its ability to lyse intracoronary thrombi? Circulation. 79:1989;1125-1136.
9. Kloner R.A., Rude R.E., Carlson N., Maroko P.R., DeBoer L.W.V., Braunwald E. Ultrastructural evidence of microvascular damage and myocardial cell injury following coronary artery occlusion which comes first? Circulation. 62:1980;178-184.
10. Ito H., Maruyama A., Iwakura K., et al. Clinical implications of the "no reflow" phenomenon a predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction . Circulation. 93:1996;223-228.
11. Kunichika H, Ben-Yehuda O, Lafitte S, Kunichika N, Peters B, DeMaria AN. Effects of glycoprotein IIb/IIIa inhibition on microvascular flow after coronary reperfusion: a quantitative myocardial contrast echocardiography study. J Am Coll Cardiol 2004;43:276-83.
12. Reffelmann T., Kloner R.A. Is microvascular protection by cariporide and ischemic preconditioning causally linked to myocardial salvage? Am J Physiol Heart Circ Physiol. 284:2003;H1134-1141.
13. Hale S.L., Dae M.W., Kloner R.A. Hypothermia during reperfusion limits "no-reflow" injury in a rabbit model of acute myocardial infarction. Cardiovasc Res. 59:2003;715-722.
14. Zhao X.-Q., Theroux P., Snapinn S.M., et al. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction angiographic results from the PRISM-PLUS trial (platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms) . Circulation. 100:1999;1609-1615.
15. de Lemos J.A., Antman E.M., Gibson C.M., et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction observation from the TIMI 14 trial . Circulation. 101:2000;239-243.
16. Neumann F.J., Blasini R., Schmitt C., et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation. 98:1998;2695-2701.
17. Gibson C.M., Cohen D.J., Cohen E.A., et al. Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy). Am J Cardiol. 87:2001;1293-1295.
18. Topol E.J., Yadav J.S. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation. 101:2000;570-580.
19. Hellstrom H.R. The injury-spasm (ischemia-based hemostatic vasoconstrictive) and vascular autoregulatory hypothesis of ischemic disease resistance vessel-spasm hypothesis of ischemic disease . Am J Cardiol. 49:1982;802-810.
20. Przyklenk K., Kloner R.A. Reperfusion injury by oxygen-free radicals? Effect of superoxide dismutase plus catalase, given at the time of reperfusion, on myocardial infarct size, contractile function, coronary microvasculature, and regional myocardial blood flow. Circ Res. 64:1989;86-96.
21. Reffelmann T., Kloner R.A. Can anatomic no-reflow be prevented by pharmacologic treatment with adenosine and verapamil (abstr)? J Am Coll Cardiol. 41:(Suppl A):2003;401A.